James G. Kahn, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
James G. Kahn, MD, MPH

Professor in Residence, Department of Epidemiology and Biostatistics, School of Medicine, UCSF

jgkahn@ucsf.edu

Phone: (415) 476-6642
Box 0936, UCSF
San Francisco, CA 94143-0936

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Cancer, Immunity, and Microenvironment

Selected Publications

  1. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016 Jan 1; 176(1):65-73.
    View on PubMed
  2. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda. PLoS One. 2015; 10(12):e0143433.
    View on PubMed
  3. Understanding Cost-Effectiveness Analyses: An Explanation Using Three Different Analyses of Lung Cancer Screening. AJR Am J Roentgenol. 2015 Aug; 205(2):344-7.
    View on PubMed
  4. Research ethics and health care reform. Science. 2015 Jun 19; 348(6241):1325-6.
    View on PubMed
  5. Are long-lasting insecticide-treated bednets and water filters cost-effective tools for delaying HIV disease progression in Kenya? Glob Health Action. 2015; 8:27695.
    View on PubMed
  6. Correction: Cost-Effectiveness Of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2015; 10(4):e0126988.
    View on PubMed
  7. Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar. Malar J. 2015; 14(1):55.
    View on PubMed
  8. Saving lives and saving money: Hospital-based violence intervention is cost-effective. J Trauma Acute Care Surg. 2015 Feb; 78(2):252-8.
    View on PubMed
  9. Cost-effectiveness of the non-pneumatic anti-shock garment (NASG): evidence from a cluster randomized controlled trial in Zambia and Zimbabwe. BMC Health Serv Res. 2015; 15(1):37.
    View on PubMed
  10. Relative risk reduction is useful metric to standardize effect size for public heath interventions for translational research. J Clin Epidemiol. 2015 Mar; 68(3):317-23.
    View on PubMed
  11. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015 Feb 1; 93(2):118-24.
    View on PubMed
  12. Billing and insurance-related administrative costs in United States' health care: synthesis of micro-costing evidence. BMC Health Serv Res. 2014; 14:556.
    View on PubMed
  13. Cost-effectiveness research in neurosurgery. Neurosurg Clin N Am. 2015 Apr; 26(2):189-96, viii.
    View on PubMed
  14. Surgery is cost-effective treatment for young patients with vestibular schwannomas: decision tree modeling of surgery, radiation, and observation. Neurosurg Focus. 2014 Nov; 37(5):E8.
    View on PubMed
  15. Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One. 2014; 9(9):e107255.
    View on PubMed
  16. Avahan and the cost-effectiveness of "prevention as prevention". Lancet Glob Health. 2014 Sep; 2(9):e493-4.
    View on PubMed
  17. Global cost-effectiveness of GDM screening and management: Current knowledge and future needs. Best Pract Res Clin Obstet Gynaecol. 2015 Feb; 29(2):206-24.
    View on PubMed
  18. Modeling scenarios for the end of AIDS. Clin Infect Dis. 2014 Jul; 59 Suppl 1:S16-20.
    View on PubMed
  19. Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries. BMJ Open. 2014; 4(6):e003987.
    View on PubMed
  20. Integrated disease prevention campaigns: assessing country opportunity for implementation via an index approach. BMJ Open. 2014; 4(3):e004308.
    View on PubMed

Go to UCSF Profiles, powered by CTSI